Expanding Therapeutic Horizons in Parkinson's Disease Through MicroRNA‐Based Interventions: A Comprehensive Review
- 29 November 2025
- journal article
- review article
- Published by Wiley in European Journal of Neuroscience
- Vol. 62 (11) , e70343
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder with rapidly increasing prevalence, characterized by dopaminergic neuronal loss and α‐synuclein aggregation. Current therapies provide only symptomatic benefit and do not alter the disease course. MicroRNAs (miRNAs), small noncoding RNAs that regulate gene expression, are increasingly recognized as key modulators of PD pathogenesis, influencing oxidative stress, mitochondrial dysfunction, neuroinflammation, and proteostasis. Therapeutic modulation of miRNAs in PD has centered on two complementary approaches: miRNA inhibitors (antagomiRs), which silence pathogenic miRNAs, and miRNA mimics (agomiRs), which restore the activity of protective ones. This review integrates current insights into miRNA dysregulation in PD and evaluates the hurdles limiting therapeutic translation. Specific miRNAs such as miR‐7, miR‐153, and miR‐34b/c directly regulate SNCA expression, whereas others influence clearance pathways and stress responses. Although miRNA‐based therapeutics offer considerable promise, their clinical utility remains constrained by challenges of delivery, specificity, and standardization. This review highlights strategies to harness miRNA modulation as a targeted therapeutic avenue in PD.Keywords
This publication has 131 references indexed in Scilit:
- Unlocking Parkinson’s disease: the role of microRNAs in regulation, diagnosis, and therapyApoptosis, 2025
- Exosome‐Based Theranostic for Gastrointestinal Cancer: Advances in Biomarker Discovery and Therapeutic EngineeringSmall Methods, 2025
- Shaping the course of early-onset Parkinson’s disease: insights from a longitudinal cohortNeurological Sciences, 2023
- Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa TherapyJAMA Neurology, 2021
- MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson’s Disease Models by Directly Targeting MEF2DNeurochemical Research, 2020
- Chitosan-Based Systems for Gene Delivery2019
- Lipid Peroxidation and Mitochondrial Dysfunction in Alzheimer's and Parkinson's Diseases: Role of Natural Products as Cytoprotective Agents2017
- Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s DiseaseNeuroMolecular Medicine, 2014
- Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer’s and Parkinson’s diseasesApoptosis, 2010
- A microRNA Feedback Circuit in Midbrain Dopamine Neurons2009